论文部分内容阅读
目的探讨肺耐药蛋白(lung resistance protein,LRP),DNA拓扑异构酶Ⅱ(topoisomeraseⅡ,TOPOⅡ),谷胱甘肽-S-转移酶-π(glutathione-S-transferase-π,GST-π)在非小细胞肺癌(non-small cell lung cancer,NSCLC)的表达及其临床意义。方法采用免疫组化技术(S-P法)检测57例术前均未进行化疗的非小细胞肺癌中LRP、TOPOⅡ及GST-π的表达情况。结果在NSCLC中LRP、TOPOⅡ及GST-π的表达阳性率分别为68.42%(39/57),66.67%(38/57)和84.21%(48/57),三者的表达均与病人的年龄、性别、肿瘤的大体类型、淋巴结转移以及临床分期无关(P>0.05),而与肿瘤的分化程度相关,高中分化与低分化之间差异有显著性(P<0.05)。且TOPOⅡ表达与组织学类型相关,鳞癌组的表达显著高于腺癌和细支气管肺泡癌(P<0.05)。结论LRP、GST-π和TOPOⅡ共同参与了NSCLC的固有耐药,表达的差异提示对药物敏感度不同,联合检测为制定科学有效的治疗方案具有临床意义。
Objective To investigate the expression of lung resistance protein (LRP), topoisomeraseⅡ (TOPOⅡ), glutathione-S-transferase-π (GST-π) In non-small cell lung cancer (NSCLC) and its clinical significance. Methods The expression of LRP, TOPO Ⅱ and GST-π in 57 patients with non-small cell lung cancer who had not undergone chemotherapy before operation were detected by immunohistochemistry (S-P method). Results The positive rates of LRP, TOPOⅡ and GST-π in NSCLC were 68.42% (39/57), 66.67% (38/57) and 84.21% (48/57), respectively. The expressions of LRP, TOPOⅡ and GST- , Gender, type of tumor, lymph node metastasis and clinical stage (P> 0.05). However, there was a significant difference between high school differentiation and poor differentiation (P <0.05). The expression of TOPO Ⅱ was correlated with the histological type. The expression of TOPO Ⅱ in squamous cell carcinoma was significantly higher than that in adenocarcinoma and bronchioloalveolar carcinoma (P <0.05). Conclusions LRP, GST-π and TOPOⅡ are involved in the intrinsic drug resistance of NSCLC. The difference in expression indicates different sensitivity to drugs. The combination detection of LRP, GST-π and TOPOⅡ is of clinical significance for the development of a scientific and effective treatment regimen.